Glukóza Viaflo Baxter (Glucose Monohydrate)

Glukóza Viaflo Baxter is indicated for several clinical situations where rapid glucose supplementation or fluid balance is required.

• Treatment of acute hypoglycemia when oral glucose is not feasible.
• Component of parenteral nutrition regimens to provide carbohydrate calories.
• Support of fluid and electrolyte replacement during surgery or critical illness.
• Management of glucose deficits in patients receiving prolonged fasting.
• Adjunctive therapy for patients with insulin‑dependent diabetes experiencing severe low blood sugar.

Intravenous administration of glucose solutions can be associated with both common and less frequent adverse reactions.

Common

• Mild hyperglycemia.
• Local irritation at the injection site.
• Nausea or vomiting.
• Headache.
• Transient electrolyte shifts (e.g., low potassium).
• Transient increase in serum osmolality.

Serious

• Severe hyperglycemia leading to osmotic diuresis.
• Allergic or anaphylactic reaction to the formulation.
• Hyperosmolar hyperglycemic state.
• Fluid overload causing pulmonary edema.
• Metabolic acidosis in susceptible patients.
• Seizures related to severe electrolyte imbalance.

Before using Glukóza Viaflo Baxter, clinicians should consider several precautionary measures to ensure safe administration.

• Verify blood glucose level and avoid administration if hyperglycemia is present.
• Adjust dose in patients with renal or hepatic impairment.
• Monitor electrolyte concentrations, especially potassium and sodium, during therapy.
• Use caution in patients with heart failure or at risk of fluid overload.
• Assess for history of hypersensitivity to glucose solutions or excipients.
• Avoid rapid infusion rates unless clinically indicated.
• Ensure aseptic technique to prevent catheter‑related infections.

Glucose infusion may interact with other medications or clinical conditions, requiring attention to avoid adverse outcomes.

Avoid

• Co‑administration with insulin without appropriate glucose monitoring.
• Concurrent use of high‑dose diuretics that may exacerbate electrolyte disturbances.
• Administration with hypertonic saline solutions that could increase osmolar load.

Use with caution

• Beta‑blockers, which may mask signs of hypoglycemia.
• Corticosteroids, which can raise blood glucose levels.
• Catecholamines (e.g., epinephrine) that may affect glucose metabolism.
• Sodium‑glucose cotransporter‑2 (SGLT2) inhibitors, requiring close monitoring.
• Total parenteral nutrition mixtures, to prevent excessive carbohydrate load.